‘The World Regenerative Medicine Revenues Will Reach $8.84bn in 2021′ Says Brand New visiongain Report

LONDON, July 28, 2011 -

www.visiongain.com/Report/652/Translational-Regenerative-Medicine-Market-Prospects-2011-2021

A new report by visiongain, a London-based business information company, predicts that world regenerative medicine revenues will reach $8.84bn in 2021. That market generated $0.82bn in 2010, according to Translational Regenerative Medicine: Market Prospects 2011-2021, published in July 2011.

Novel treatment options are in increasing demand as a result of growing disease prevalence worldwide. Regenerative medicine offers the opportunity to treat and cure many health disorders, including cancers and cardiovascular diseases. The regenerative medicine market will grow rapidly this decade, driven by the approval of new tissue engineered products, stem cell treatments and gene therapies. Growth will be most rapid in emerging markets, visiongain’s analysis shows.

Richard Lang, pharmaceutical industry analyst, said: “The world regenerative medicine market will benefit most from the entry of new products, especially in the US and Europe. Challenges in moving products from bench to bedside must still be overcome, however. Regulatory hurdles, scaling up manufacturing and product reimbursement will be the most prominent of these challenges from 2011 onwards.”

In 2010, autologous chondrocyte implantations and skin substitutes for diabetic foot ulcers constituted the largest sectors of the regenerative medicine market. These sectors will remain important, with aging world populations and rising diabetes prevalence, the report notes. Development of new products will lead to the greatest market growth, however. Stem cell and gene therapies targeting cardiovascular disorders represent the most promising products candidates from 2011 to 2021.

Visiongain forecasts that the overall regenerative medicine market will grow rapidly to 2021. Experience gained from the past two decades will quicken the pace of product approvals in the next ten years. The future of regenerative medicine is promising, as a result of increasing demand in many therapeutic areas and improved product development techniques, the published report concludes. This new study adds to visiongain’s wide range of analytical reports in healthcare and other industry areas.  

For sample pages of the report please click on:

www.visiongain.com/Report/652/Translational-Regenerative-Medicine-Market-Prospects-2011-2021

Table of Contents

1. Executive Summary
1.1 Regenerative Medicine Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. Translational Regenerative Medicine: An Introduction
2.1 Regenerative Medicine
2.1.1 Stem Cell Therapy
2.1.2 Gene Therapy
2.1.2.1 Gene Delivery and Viral Vectors
2.1.3 Tissue Engineering
2.2 Translational Regenerative Medicine
2.2.1 Scope of this Report
2.2.2 Products Not Covered by this Report
2.2.2.1 Cosmetic Applications for Regenerative Medicine

3. The Global Regenerative Medicine Market 2011-2021
3.1 Global Regenerative Medicine Market 2010
3.2 Global Regenerative Medicine Market Forecast 2011-2021
3.3 Tissue Engineered Products Market 2010
3.3.1 Wound Repair
3.3.1.1 Dermagraft (Advanced BioHealing/Shire)
3.3.1.2 Apligraf (Organogenesis)
3.3.2 Autologous Chondrocyte Implantation (ACI)
3.3.2.1 ChondroCelect (TiGenix)
3.3.2.2 Carticel (Genzyme)
3.3.3 ACI Pipeline 2011
3.3.4 Tissue Engineering Market Forecast 2011-2021
3.4 Stem Cell Therapy Market 2010
3.4.1 Bone Marrow Transplants
3.4.2 Celution System (Cytori Therapeutics)
3.4.3 Bone Regeneration
3.4.3.1 Osteocel Plus (NuVasive/Osiris Therapeutics)
3.4.3.2 Trinity Evolution (Orthofix)
3.4.3.3 AlloStem (AlloSource)
3.4.3.4 PureGen (AlphaTec Spine)
3.4.4 Stem Cell Therapy Market Forecast
3.5 Gene Therapy
3.5.1 A Market Restricted to Asia
3.5.2 Near-Term Gene Therapy Pipeline
3.5.2.1 Glybera (Alipogene Tiparvovec, Amsterdam Molecular Therapeutics)
3.5.2.2 Collategene (Beperminogene Perplasmid, Vical/AnGes MG)
3.5.2.3 Allovectin-7 (Vical)
3.5.2.4 Trinam (Taberminogene Vadenovec, Ark Therapeutics)
3.5.3 Gene Therapy Market Forecast 2011-2021
3.5.4 Gene Therapy Late-Stage Failures

4. Leading Regenerative Medicine Companies
4.1 Advanced Cell Technology
4.2 Amsterdam Molecular Therapeutics (AMT)
4.2.1 Haemophilia B
4.2.2 Duchenne Muscular Dystrophy
4.3 Ark Therapeutics
4.4 BioTissue
4.5 Cardio3 Biosciences
4.6 Celgene
4.6.1 LifebankUSA
4.7 Co.don
4.8 Genzyme
4.9 Geron
4.9.1 Geron and GE Healthcare
4.10 Japanese Tissue Engineering Co (J-TEC)
4.11 Mesoblast
4.11.1 Cephalon Acquires Stake in Mesoblast
4.12 Opexa Therapeutics
4.13 Organogenesis
4.14 Osiris Therapeutics
4.14.1 Chondrogen
4.14.2 Prochymal
4.15 Oxford BioMedica
4.16 ReNeuron
4.17 Tengion
4.18 TiGenix
4.18.1 TiGenix Merges with Cellerix

5. Leading Applications for Regenerative Medicine 2011-2021
5.1 Diabetes
5.1.1 Diabetic Foot Ulcers
5.1.2 Diabetes and Stem Cell Therapy
5.1.2.1 Novo Nordisk and Cellartis
5.1.2.2 AstraZeneca
5.1.2.3 Eli Lilly
5.1.3 Diabetes and Gene Therapy
5.2 Cardiovascular Disease
5.2.1 Stem Cell Therapy
5.2.1.1 Revascor (Mesoblast)
5.2.2 Cardiovascular Disease Gene Therapy
5.2.2.1 Generx (Alferminogene Tadenovec, Cardium)
5.2.3 Tissue Engineering for Cardiovascular Disease
5.3 Cancer
5.3.1 OncoCyte/BioTime
5.3.2 Cancer and Gene Therapy
5.3.2.1 Thymidine Kinase
5.4 CNS Diseases
5.4.1 Stem Cell Therapy
5.4.2 Ceregene and CNS Gene Therapy
5.5 Eye Diseases
5.5.1 Stem Cell Therapy
5.5.1.1 EyeCyte
5.5.2 Gene Therapy
5.5.3 Tissue Engineering
5.6 Organ Transplants

6. Trends in Translational Regenerative Medicine 2011-2021
6.1 SWOT Analysis for Translational Regenerative Medicine 2011-2021
6.1.1 Market Opportunities and Threats
6.1.1.1 Commercialising Regenerative Medicine
6.1.1.2 Medical Tourism as an Opportunity and a Threat
6.2 STEP Analysis for Translational Regenerative Medicine 2011-2021
6.3 Social Factors
6.3.1 Ethical Concerns with Regenerative Medicine
6.3.1.1 Human Embryonic Stem Cell Research in the US
6.3.2 Immune Response
6.3.2.1 Graft Versus Host Disease (GvHD)
6.3.2.2 Gene Therapy and Immune Response
6.4 Technological Developments
6.4.1 Nanotechnology in Regenerative Medicine
6.4.2 Manufacturing and Scalability
6.4.2.1 Bioreactors
6.4.2.2 Case Study: Humacyte and Xcellerex
6.5 Economic Pressures
6.5.1 High Risk, High Reward
6.5.2 Big Pharma Investment to Drive Growth
6.5.2.1 Stem Cell Therapy
6.5.2.2 Gene Therapy
6.5.2.3 Tissue Engineering
6.5.3 Government and Public Funding for Regenerative Medicine
6.5.3.1 California Institute for Regenerative Medicine (CIRM)
6.5.3.2 Armed Forces Institute of Regenerative Medicine (AFIRM)
6.6 Political Issues
6.6.1 Regulatory Hurdles
6.6.2 Regenerative Medicine Reimbursement
6.6.2.1 Reimbursement in the US
6.6.2.2 Reimbursement in the EU
6.6.3 The Intellectual Property Landscape

7. Regional Analysis of the Regenerative Medicine Market 2011-2021
7.1 Regional Breakdown of the Regenerative Medicine Market 2010
7.2 Regional Regenerative Medicine Market Forecast 2011-2021
7.3 The US
7.3.1 US Regenerative Medicine Regulation
7.3.1.1 Regenerative Medicine Promotion Act
7.3.2 US Regenerative Medicine Market Forecast 2011-2021
7.4 Europe
7.4.1 European Regenerative Medicine Regulation
7.4.2 REMEDiE
7.4.3 European Regenerative Medicine Market Forecast 2011-2021
7.5 Asia Pacific
7.5.1 Japan
7.5.2 China
7.5.3 India
7.5.4 Asia Pacific Regenerative Medicine Market Forecast 2011-2021

8. Expert Opinions from Our Industry Survey
8.1 Cardio3 Biosciences
8.1.1 Challenges for Stem Cell Therapies
8.1.2 Unmet Needs for Cardiovascular Disease
8.1.3 Autologous vs. Allogeneic Therapies
8.1.4 Regenerative Medicine for Cardiovascular Indications
8.2 Neil Warma, President and CEO, Opexa Therapeutics
8.2.1 Challenges in Developing and Commercialising Regenerative Cellular Therapies
8.2.2 Regenerative Medicine: Market Drivers
8.2.3 Autologous vs. Allogeneic Therapies
8.2.4 Potential Uses for T-Cell Therapies

9. Conclusions
9.1 The Regenerative Medicine Market 2010
9.2 Growth in the Regenerative Medicine Market from 2011-2021
9.3 US Dominance of the Tissue Engineering Market
9.4 Opportunities in Developing Regenerative Medicines from 2011-2021
9.5 Challenges in Developing Regenerative Medicines from 2011-2021

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms, Energy, Defence and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

To request an exec summary o the report please contact Sara Peerun on:

Email: sara.peerun@visiongainglobal.com
Tel: +44(0)207-3366100
Web: www.visiongain.com

.